Search: onr:"swepub:oai:prod.swepub.kib.ki.se:142190212" >
Plasma potassium ra...
Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project
-
- Gasparini, A (author)
- Karolinska Institutet
-
- Evans, M (author)
- Karolinska Institutet
-
- Barany, P (author)
- Karolinska Institutet
-
show more...
-
Xu, HR (author)
-
- Jernberg, T (author)
- Karolinska Institutet
-
- Arnlov, J (author)
- Karolinska Institutet
-
- Lund, LH (author)
- Karolinska Institutet
-
- Carrero, JJ (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2018-08-06
- 2019
- English.
-
In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. - : Oxford University Press (OUP). - 1460-2385. ; 34:9, s. 1534-1541
- Related links:
-
https://academic.oup...
-
show more...
-
http://kipublication...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- BackgroundSmall-scale studies suggest that hyperkalaemia is a less threatening condition in chronic kidney disease (CKD), arguing adaptation/tolerance to potassium (K+) retention. This study formally evaluates this hypothesis by estimating the distribution of plasma K+ and its association with mortality across CKD stages.MethodsThis observational study included all patients undergoing plasma K+ testing in Stockholm during 2006–11. We randomly selected one K+ measurement per patient and constructed a cross-sectional cohort with mortality follow-up. Covariates included demographics, comorbidities, medications and estimated glomerular filtration rate (eGFR). We estimated K+ distribution and defined K+ ranges associated with 90-, 180- and 365-day mortality.ResultsIncluded were 831 760 participants, of which 70 403 (8.5%) had CKD G3 (eGFR <60–30 mL/min) and 8594 (1.1%) had CKD G4–G5 (eGFR <30 mL/min). About 66 317 deaths occurred within a year. Adjusted plasma K+ increased across worse CKD stages: from median 3.98 (95% confidence interval 3.49–4.59) for eGFR >90 to 4.43 (3.22–5.65) mmol/L for eGFR ≤15 mL/min/1.73 m2. The association between K+ and mortality was U-shaped, but it flattened at lower eGFR strata and shifted upwards. For instance, the range where the 90-day mortality risk increased by no more than 100% was 3.45–4.94 mmol/L in eGFR >60 mL/min, but was 3.36–5.18 in G3 and 3.26–5.53 mmol/L in G4–G5. In conclusion, CKD stage modifies K+ distribution and the ranges that predict mortality in the community.ConclusionAlthough this study supports the view that hyperkalaemia is better tolerated with worse CKD, it challenges the current use of a single optimal K+ range for all patients.
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database